These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 9533544

  • 1. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
    Zamboni WC, Stewart CF, Cheshire PJ, Richmond LB, Hanna SK, Luo X, Poquette C, McGovren JP, Houghton JA, Houghton PJ.
    Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
    Thompson J, Zamboni WC, Cheshire PJ, Lutz L, Luo X, Li Y, Houghton JA, Stewart CF, Houghton PJ.
    Clin Cancer Res; 1997 Mar; 3(3):423-31. PubMed ID: 9815701
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
    Houghton JA, Cheshire PJ, Hallman JD, Lutz L, Luo X, Li Y, Houghton PJ.
    Clin Cancer Res; 1996 Jan; 2(1):107-18. PubMed ID: 9816097
    [Abstract] [Full Text] [Related]

  • 4. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.
    Zamboni WC, Houghton PJ, Thompson J, Cheshire PJ, Hanna SK, Richmond LB, Lou X, Stewart CF.
    Clin Cancer Res; 1998 Feb; 4(2):455-62. PubMed ID: 9516936
    [Abstract] [Full Text] [Related]

  • 5. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice.
    Stewart CF, Zamboni WC, Crom WR, Houghton PJ.
    Cancer Chemother Pharmacol; 1997 Feb; 40(3):259-65. PubMed ID: 9219511
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
    Houghton PJ, Cheshire PJ, Hallman JD, Lutz L, Friedman HS, Danks MK, Houghton JA.
    Cancer Chemother Pharmacol; 1995 Feb; 36(5):393-403. PubMed ID: 7634381
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
    Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, Houghton JA.
    Cancer Chemother Pharmacol; 1992 Feb; 31(3):229-39. PubMed ID: 1464161
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of oral irinotecan against neuroblastoma xenografts.
    Thompson J, Zamboni WC, Cheshire PJ, Richmond L, Luo X, Houghton JA, Stewart CF, Houghton PJ.
    Anticancer Drugs; 1997 Apr; 8(4):313-22. PubMed ID: 9180383
    [Abstract] [Full Text] [Related]

  • 9. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
    Kawato Y, Furuta T, Aonuma M, Yasuoka M, Yokokura T, Matsumoto K.
    Cancer Chemother Pharmacol; 1991 Apr; 28(3):192-8. PubMed ID: 1855276
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
    Houghton PJ, Cheshire PJ, Hallman JC, Bissery MC, Mathieu-Boué A, Houghton JA.
    Cancer Res; 1993 Jun 15; 53(12):2823-9. PubMed ID: 8504425
    [Abstract] [Full Text] [Related]

  • 11. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice.
    Vassal G, Boland I, Santos A, Bissery MC, Terrier-Lacombe MJ, Morizet J, Sainte-Rose C, Lellouch-Tubiana A, Kalifa C, Gouyette A.
    Int J Cancer; 1997 Sep 26; 73(1):156-63. PubMed ID: 9334824
    [Abstract] [Full Text] [Related]

  • 12. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
    Bissery MC, Vrignaud P, Lavelle F, Chabot GG.
    Anticancer Drugs; 1996 Jun 26; 7(4):437-60. PubMed ID: 8826613
    [Abstract] [Full Text] [Related]

  • 13. Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.
    Chester JD, Joel SP, Cheeseman SL, Hall GD, Braun MS, Perry J, Davis T, Button CJ, Seymour MT.
    J Clin Oncol; 2003 Mar 15; 21(6):1125-32. PubMed ID: 12637480
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of treatment of colon, lung and breast human carcinoma xenografts with: doxorubicin, cisplatin, irinotecan or topotecan.
    Hardman WE, Moyer MP, Cameron IL.
    Anticancer Res; 1999 Mar 15; 19(3B):2269-74. PubMed ID: 10472342
    [Abstract] [Full Text] [Related]

  • 15. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
    Houghton PJ, Stewart CF, Cheshire PJ, Richmond LB, Kirstein MN, Poquette CA, Tan M, Friedman HS, Brent TP.
    Clin Cancer Res; 2000 Oct 15; 6(10):4110-8. PubMed ID: 11051264
    [Abstract] [Full Text] [Related]

  • 16. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
    Neijzen R, Wong MQ, Gill N, Wang H, Karim T, Anantha M, Strutt D, Waterhouse D, Bally MB, Tai IT, Ng SS, Yapp DT.
    J Control Release; 2015 Feb 10; 199():72-83. PubMed ID: 25497312
    [Abstract] [Full Text] [Related]

  • 17. Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.
    Woo MH, Peterson JK, Billups C, Liang H, Bjornsti MA, Houghton PJ.
    Cancer Chemother Pharmacol; 2005 May 10; 55(5):411-9. PubMed ID: 15503024
    [Abstract] [Full Text] [Related]

  • 18. Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002.
    Shinohara H, Killion JJ, Kuniyasu H, Kumar R, Fidler IJ.
    Clin Cancer Res; 1998 Sep 10; 4(9):2053-63. PubMed ID: 9748119
    [Abstract] [Full Text] [Related]

  • 19. Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts.
    Zamboni WC, Jung LL, Egorin MJ, Hamburger DR, Joseph E, Jin R, Strychor S, Ramanathan RK, Eiseman JL.
    Clin Cancer Res; 2005 Jul 01; 11(13):4867-74. PubMed ID: 16000585
    [Abstract] [Full Text] [Related]

  • 20. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
    Britten CD, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman S.
    Cancer Res; 1999 Mar 01; 59(5):1049-53. PubMed ID: 10070962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.